Objective: This study aimed to investigate the therapeutic effects of recombinant human GH (rhGH) combined with low-dose stanozolol on the growth and final adult height (FAH) of girls with Turner syndrome (TS).
Method: A total of 47 girls with TS were treated with rhGH (47.652.4 μg/kg per day) and low-dose stanozolol (2035 μg/kg per day), starting at a mean age of 12.57±1.96 year. The control group consisted of 26 girls with TS, who did not receive treatment. Subjects growth velocity (GV) was investigated. Height SDS (HtSDS), as referenced by the healthy Chinese girls (HtSDSNor) and as well as the untreated Chinese girls with TS (HtSDSTS), were calculated. Post-treatment follow-up was performed until the subjects achieved FAH or near-FAH.
Results: FAH was significantly higher in subjects receiving treatment compared to the untreated controls (151.42 vs 136.72 cm, P<0.001). GV was significantly higher in the first to fourth years of treatment compared to baseline values (P<0.001); it was significantly lower in the second to fifth years of treatment compared to the first year (P<0.001).
Conclusions: In girls with TS 912 years of age, rhGH combined with low-dose stanozolol may effectively increase growth. At least a 2-year course of this treatment may effectively improve FAH with proper delay of estrogen-induced development.
20 - 22 Sep 2014
European Society for Paediatric Endocrinology